Excerpt: … Results; Shares Up 12.1% YTD – Look Ahead: ∙ Adj EPS est $9.45 (Cons) ∙ Revenue est $3b ∙ EYLEA US net product sales est $1.54b ∙ Dupixent US net product sales est $1.86b — Read more: https://www.smartkarma.com/entities/regeneron-pharmaceuticals
stocktwits.com • (Opens in a new window) ⧉
Are you a Professional Journalist?
The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.
